Eradivir Secures $10.25M for Influenza Study
Biotech firm Eradivir raises $10.25M for Phase 2a EV25 study, aiming to revolutionize influenza treatment.
- Latest
- Trending
Biotech firm Eradivir raises $10.25M for Phase 2a EV25 study, aiming to revolutionize influenza treatment.
Moderna shares dip as R&D spending reduces, focusing on FDA approval for 10 key products including RSV and cancer treatments.
Medera aims for Nasdaq listing via SPAC to boost gene therapies, spotlighting rare biotech SPACs in 2024.
Boehringer Ingelheim acquires Saiba Animal Health, boosting pet R&D with innovative therapeutic vaccines.
AI SPERA partners with Hackers Central to introduce top-tier cyber solutions like 'Criminal IP ASM' to Mexico's security market.
Microsoft fixes zero-day flaw in Windows exploited by North Korea's Lazarus Group to gain system privileges.
Brain Cipher ransomware targets Indonesia, uses multiple identities to evade detection, causing disruptions.
Discover GrimResource: A new hacking method exploiting Microsoft Management Console files. Learn how to protect yourself from this emerging threat.
Bharat Biotech admits patent oversight on Covaxin, pledges to include ICMR scientists in new filings to uphold transparency and legal ...
US sanctions 12 Kaspersky Lab execs over Russia ties; bans software sales and updates in the US, urging users to ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.